NORCROSS, Ga.--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, today announced that equity analysis firm EquityNet Research has initiated paid research coverage of the Company with a detailed report that recommends a “Buy” rating, and projects a 12-month share price target of $4.17.
